A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations. (Q54281304)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations. (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Konstanze Döhner

13

object named as

Konstanze Döhner

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

Hartmut Döhner

15

object named as

Hartmut Döhner

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

Gudrun Göhring

9

object named as

Gudrun Göhring

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

author name string

Walter Fiedler

1

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Sabine Kayser

2

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Maxim Kebenko

3

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Melanie Janning

4

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Jürgen Krauter

5

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Marcus Schittenhelm

6

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Katharina Götze

7

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Daniela Weber

8

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Veronica Teleanu

10

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Felicitas Thol

11

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Michael Heuser

12

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Arnold Ganser

14

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Richard F Schlenk

16

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

language of work or name

0 references

publication date

29 March 2015

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

169

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

5

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

694-700

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations

1 reference

https://api.crossref.org/works/10.1111/BJH.13353

21 January 2018

Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status

1 reference

https://api.crossref.org/works/10.1111/BJH.13353

21 January 2018

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1111/BJH.13353

21 January 2018

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

1 reference

https://api.crossref.org/works/10.1111/BJH.13353

21 January 2018

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

1 reference

https://api.crossref.org/works/10.1111/BJH.13353

21 January 2018

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

1 reference

https://api.crossref.org/works/10.1111/BJH.13353

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1111/BJH.13353

21 January 2018

Functional heterogeneity of genetically defined subclones in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111/BJH.13353

21 January 2018

A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186.

1 reference

https://api.crossref.org/works/10.1111/BJH.13353

21 January 2018

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1111/BJH.13353

21 January 2018

Selective FLT3 inhibition of FLT3-ITD acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns

1 reference

https://api.crossref.org/works/10.1111/BJH.13353

21 January 2018

Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111/BJH.13353

21 January 2018

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1111/BJH.13353

21 January 2018

Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1111/BJH.13353

21 January 2018

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111/BJH.13353

21 January 2018

The evolving molecular genetic landscape in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1111/BJH.13353

21 January 2018

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111/BJH.13353

21 January 2018

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111/BJH.13353

21 January 2018

Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1111/BJH.13353

21 January 2018

Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells

1 reference

https://api.crossref.org/works/10.1111/BJH.13353

21 January 2018

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1111/BJH.13353

21 January 2018

Identifiers

10.1111/BJH.13353

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 May 2018

http://europepmc.org/abstract/MED/25818407

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54281304&oldid=1404513736"